Felix Lorenz is the CEO and CSO of Captain T Cell, a Berlin-Schönefeld-based biotech pioneering next-generation TCR-T cell therapies for solid tumors. A cancer immunologist turned entrepreneur, he has steered Captain T Cell from academic spin-out to a venture-backed company with over €15 million secured in funding. Felix builds agile, cross-functional teams to translate cutting-edge immunology into transformative treatments for end-stage cancer patients. Under his leadership, the company has expanded rapidly, attracted top talent, and earned accolades at Bayer Startup Spotlight and other start-up competitions. Felix holds a Ph.D. in Molecular Immunology from Humboldt University Berlin and has authored multiple patents advancing TCR engineering. He thrives at the intersection of science, entrepreneurship, and clinical innovation.